{
  "metadata": {
    "case_id": 52,
    "model": "Claude-4.5-Sonnet",
    "timestamp": "2025-11-29T16:46:16.181633",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/52_NCT03587207.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Claude-4.5-Sonnet/52_Claude-4.5-Sonnet.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 5,
      "pred_count": 5,
      "similarity_matrix": [
        [
          0.98,
          0.6,
          0.7,
          0.8,
          0.4
        ],
        [
          0.82,
          0.9,
          0.92,
          0.7,
          0.62
        ],
        [
          0.55,
          0.86,
          0.92,
          0.7,
          0.7
        ],
        [
          0.64,
          0.55,
          0.7,
          0.92,
          0.65
        ],
        [
          0.78,
          0.6,
          0.65,
          0.6,
          0.96
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "label": "MenABCWY Group",
            "type": "EXPERIMENTAL",
            "description": "Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenABCWY twice, 2 months apart (Day 1 and Day 61).",
            "interventionNames": [
              "Biological: MenABCWY vaccine"
            ]
          },
          "pred_item": {
            "label": "MenABCWY",
            "type": "EXPERIMENTAL",
            "description": "Participants received two doses of the investigational MenABCWY vaccine administered intramuscularly 2 months apart (on study days 1 and 61).",
            "interventionNames": [
              "Biological: MenABCWY vaccine"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "label": "rMenBOMV+ACWY_S Group",
            "type": "ACTIVE_COMPARATOR",
            "description": "Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in the same arm twice, 2 months apart (Day 1 and Day 61).",
            "interventionNames": [
              "Biological: rMenB+OMV NZ (Bexsero) vaccine",
              "Biological: MenACWY (Menveo) vaccine"
            ]
          },
          "pred_item": {
            "label": "4CMenB+ACWY/S",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants received two doses of 4CMenB plus MenACWY vaccines administered concomitantly in the same arm (nondominant arm) 2 months apart (on study days 1 and 61). 4CMenB was injected in the upper deltoid and MenACWY in the lower deltoid of the nondominant arm.",
            "interventionNames": [
              "Biological: 4CMenB vaccine (Bexsero)",
              "Biological: MenACWY-CRM vaccine (Menveo)"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 2,
          "score": 0.92,
          "status": "matched",
          "ref_item": {
            "label": "rMenBOMV+ACWY_D Group",
            "type": "ACTIVE_COMPARATOR",
            "description": "Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) concomitantly received one dose of rMenB+OMV NZ (Bexsero) and one dose of MenACWY (Menveo) in 2 different arms twice, 2 months apart (Day 1 and Day 61).",
            "interventionNames": [
              "Biological: rMenB+OMV NZ (Bexsero) vaccine",
              "Biological: MenACWY (Menveo) vaccine"
            ]
          },
          "pred_item": {
            "label": "4CMenB+ACWY/D",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants received two doses of 4CMenB plus MenACWY vaccines administered concomitantly in different arms 2 months apart (on study days 1 and 61). 4CMenB was injected in the nondominant arm and MenACWY in the dominant arm.",
            "interventionNames": [
              "Biological: 4CMenB vaccine (Bexsero)",
              "Biological: MenACWY-CRM vaccine (Menveo)"
            ]
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": 3,
          "score": 0.92,
          "status": "matched",
          "ref_item": {
            "label": "rMenBOMV Group",
            "type": "ACTIVE_COMPARATOR",
            "description": "Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of rMenB+OMV NZ (Bexsero) twice, 2 months apart (Day 1 and Day 61).",
            "interventionNames": [
              "Biological: rMenB+OMV NZ (Bexsero) vaccine"
            ]
          },
          "pred_item": {
            "label": "4CMenB",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants received two doses of 4CMenB vaccine administered intramuscularly 2 months apart (on study days 1 and 61).",
            "interventionNames": [
              "Biological: 4CMenB vaccine (Bexsero)"
            ]
          }
        },
        {
          "ref_idx": 4,
          "pred_idx": 4,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "label": "MenACWY Group",
            "type": "ACTIVE_COMPARATOR",
            "description": "Healthy subjects between, and including, 10 to 25 years of age at the time of the first vaccination (equally distributed across the 2 age strata of 10 to 17 years and 18 to 25 years) received one dose of MenACWY (Menveo) once at Day 1, which was the first and last vaccination for MenACWY group.",
            "interventionNames": [
              "Biological: MenACWY (Menveo) vaccine"
            ]
          },
          "pred_item": {
            "label": "MenACWY",
            "type": "ACTIVE_COMPARATOR",
            "description": "Participants received a single dose of MenACWY vaccine administered intramuscularly on day 1 of the study.",
            "interventionNames": [
              "Biological: MenACWY-CRM vaccine (Menveo)"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 3,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.98,
          0.8,
          0.82
        ],
        [
          0.82,
          0.92,
          0.7
        ],
        [
          0.78,
          0.7,
          0.96
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "type": "BIOLOGICAL",
            "name": "MenABCWY vaccine",
            "description": "Two doses administered intramuscularly in the deltoid region of the non-dominant arm.",
            "armGroupLabels": [
              "MenABCWY Group"
            ]
          },
          "pred_item": {
            "type": "BIOLOGICAL",
            "name": "MenABCWY vaccine",
            "description": "Investigational vaccine prepared by reconstituting lyophilized powder containing CRM197-conjugated oligosaccharides of meningococcal serogroups A, C, W, and Y with a liquid suspension containing purified recombinant proteins from meningococcal serogroup B (NadA, fHbp, and NHBA) and outer membrane vesicle (OMV) components from serogroup B strain NZ98/254. The reconstituted formulation contained 10 μg of MenA-CRM197, 5 μg each of MenC-CRM197, MenW-CRM197, and MenY-CRM197, 50 μg of each recombinant MenB protein, 1.5 mg aluminum hydroxide, and 25 μg of OMV. A 0.5-ml dose was administered intramuscularly into the deltoid muscle.",
            "armGroupLabels": [
              "MenABCWY"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.92,
          "status": "matched",
          "ref_item": {
            "type": "BIOLOGICAL",
            "name": "rMenB+OMV NZ (Bexsero) vaccine",
            "description": "Two doses administered 2 months apart intramuscularly in the deltoid region of the non-dominant arm to subjects randomised to the rMenBOMV+ACWY\\_S Group, rMenBOMV+ACWY\\_D Group and rMenBOMV Group",
            "armGroupLabels": [
              "rMenBOMV Group",
              "rMenBOMV+ACWY_D Group",
              "rMenBOMV+ACWY_S Group"
            ]
          },
          "pred_item": {
            "type": "BIOLOGICAL",
            "name": "4CMenB vaccine (Bexsero)",
            "description": "Licensed vaccine containing 50 μg of each recombinant MenB protein (NadA, fHbp, NHBA), 1.5 mg aluminum hydroxide, and 25 μg of OMV. A 0.5-ml dose was administered intramuscularly into the deltoid muscle.",
            "armGroupLabels": [
              "4CMenB+ACWY/S",
              "4CMenB+ACWY/D",
              "4CMenB"
            ]
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 2,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "type": "BIOLOGICAL",
            "name": "MenACWY (Menveo) vaccine",
            "description": "Two doses administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the rMenBOMV+ACWY\\_S Group and rMenBOMV+ACWY\\_D Group and one dose administered intramuscularly in the deltoid region of the dominant/non-dominant arm to subjects randomised to the MenACWY Group",
            "armGroupLabels": [
              "MenACWY Group",
              "rMenBOMV+ACWY_D Group",
              "rMenBOMV+ACWY_S Group"
            ]
          },
          "pred_item": {
            "type": "BIOLOGICAL",
            "name": "MenACWY-CRM vaccine (Menveo)",
            "description": "Licensed vaccine containing 10 μg of MenA-CRM197 and 5 μg each of MenC-CRM197, MenW-CRM197, and MenY-CRM197, prepared by mixing the lyophilized MenA-CRM197 component with the liquid MenCWY-CRM197 component just before injection. A 0.5-ml dose was administered intramuscularly into the deltoid muscle.",
            "armGroupLabels": [
              "4CMenB+ACWY/S",
              "4CMenB+ACWY/D",
              "MenACWY"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 5,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.98,
          0.82
        ],
        [
          0.95,
          0.9
        ],
        [
          0.86,
          0.86
        ],
        [
          0.78,
          0.78
        ],
        [
          0.88,
          0.82
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "measure": "Human Serum Bactericidal Activity (hSBA) Adjusted Geometric Mean Titers (GMTs) Against All of N. Meningitidis Serogroup B Test Strains (Pooled), One Month After Last Vaccination.",
            "description": "hSBA titers against all of N. meningitidis serogroup B test strains were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). The serogroup B strains were grouped together to perform a pooled analysis. Adjusted means were obtained from ANCOVA model fitted to all of the Serogroup B test strains, study group, test strain and center as fixed effects; zero-centered pre-vaccination log-transformed titer was included as a continuous covariate.",
            "timeFrame": "1 month after last vaccination i.e.: at Day 91 for all groups except for the MenACWY Group"
          },
          "pred_item": {
            "measure": "Immune response against pooled serogroup B test strains measured by hSBA GMTs",
            "description": "Immune response against pooled serogroup B test strains (fHbp, NadA, PorA, and NHBA) 1 month after the last vaccination, measured by serum bactericidal assay using human complement (hSBA) geometric mean titers (GMTs).",
            "timeFrame": "1 month post-last vaccination (day 91 for groups receiving two doses; day 31 for MenACWY group)"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "hSBA Adjusted GMTs Against Each of the N. Meningitidis Serogroup B Test Strains and N. Meningitidis Serogroups A, C, W-135, and Y, One Month After Last Vaccination.",
            "description": "hSBA titers against each of the N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted means were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.",
            "timeFrame": "1 month after last vaccination i.e.: at Day 91 for all groups except the MenACWY Group, and at Day 31 for the MenACWY Group."
          },
          "pred_item": {
            "measure": "Immune response against serogroups A, C, W, and Y measured by hSBA GMTs",
            "description": "Immune response against meningococcal serogroups A, C, W, and Y 1 month after the last vaccination, measured by serum bactericidal assay using human complement (hSBA) geometric mean titers (GMTs).",
            "timeFrame": "1 month post-last vaccination (day 91 for groups receiving two doses; day 31 for MenACWY group)"
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Percentage of Subjects With hSBA Titers Greater Than or Equal to(≥) the Lower Limit of Quantitation (LLOQ) Against Each of the N. Meningitidis Serogroup B Test Strains and Serogroups A, C, W-135 and Y,One Month After Last Vaccination.",
            "description": "Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with hSBA titers ≥ LLOQ. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).",
            "timeFrame": "1 month after last vaccination i.e.: at Day 91 for all groups except the MenACWY Group, and at Day 31 for the MenACWY Group."
          },
          "pred_item": null
        },
        {
          "ref_idx": 3,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "Percentage of Subjects With a 4-fold Increase in hSBA Titers Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135 and Y, One Month After Last Vaccination.",
            "description": "Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with a 4-fold increase in hSBA titers. A 4-fold rise was defined as: a) for individuals whose pre-vaccination titers were less than (\\<) the limit of detection (LOD), the post-vaccination titers must have been ≥4-fold the LOD or ≥ the LLOQ, whichever was greater; b) for individuals whose pre-vaccination titers were ≥ the LOD and less than (\\<) the LLOQ, the post-vaccination titers must have been at least 4 times the LLOQ; and c) for individuals whose pre-vaccination titers were ≥ the LLOQ, the post-vaccination titers must have been at least 4 times the pre-vaccination titer. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).",
            "timeFrame": "1 month after last vaccination versus baseline (i.e.: at Day 91 versus Day 1 for all groups except the MenACWY Group, and at Day 31 versus Day 1 for the MenACWY Group)."
          },
          "pred_item": null
        },
        {
          "ref_idx": 4,
          "pred_idx": null,
          "score": null,
          "status": "padded",
          "ref_item": {
            "measure": "hSBA Adjusted Geometric Mean Ratios (GMRs) Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135 and Y, One Month After Last Vaccination.",
            "description": "hSBA mean ratios at 1 month after the last vaccination versus baseline were calculated in terms of GMRs i.e. as the anti-logarithm of the mean of the change from baseline of log-transformed titer values at 1 month after last vaccination and Baseline. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted means were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.",
            "timeFrame": "1 month after last vaccination versus baseline (i.e.: at Day 91 versus Day 1 for all groups except the MenACWY Group, and at Day 31 versus Day 1 for the MenACWY Group)."
          },
          "pred_item": null
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 9,
      "pred_count": 11,
      "similarity_matrix": [
        [
          0.97,
          0.78,
          0.78,
          0.6,
          0.78,
          0.05,
          0.02,
          0.02,
          0.02,
          0.08,
          0.05
        ],
        [
          0.92,
          0.9,
          0.78,
          0.82,
          0.8,
          0.05,
          0.05,
          0.05,
          0.08,
          0.05,
          0.08
        ],
        [
          0.82,
          0.86,
          0.96,
          0.7,
          0.7,
          0.05,
          0.05,
          0.05,
          0.08,
          0.05,
          0.08
        ],
        [
          0.82,
          0.84,
          0.72,
          0.98,
          0.75,
          0.08,
          0.05,
          0.12,
          0.12,
          0.12,
          0.05
        ],
        [
          0.82,
          0.82,
          0.84,
          0.78,
          0.86,
          0.12,
          0.05,
          0.02,
          0.07,
          0.05,
          0.05
        ],
        [
          0.1,
          0.08,
          0.06,
          0.05,
          0.02,
          0.97,
          0.68,
          0.7,
          0.62,
          0.68,
          0.4
        ],
        [
          0.07,
          0.08,
          0.22,
          0.05,
          0.05,
          0.4,
          0.98,
          0.7,
          0.62,
          0.82,
          0.4
        ],
        [
          0.02,
          0.05,
          0.05,
          0.05,
          0.03,
          0.55,
          0.4,
          0.98,
          0.7,
          0.78,
          0.6
        ],
        [
          0.05,
          0.1,
          0.09,
          0.12,
          0.18,
          0.58,
          0.72,
          0.82,
          0.82,
          0.82,
          0.78
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "measure": "hSBA Adjusted GMTs Against All of N. Meningitidis Serogroup B Test Strains (Pooled), One Month After First Vaccination",
            "description": "hSBA titers against all of N. meningitidis serogroup B test strains were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). The serogroup B strains were grouped together to perform a pooled analysis. Adjusted means were obtained from ANCOVA model fitted to all of the Serogroup B test strains, study group, test strain and center as fixed effects; zero-centered pre-vaccination log-transformed titer was included as a continuous covariate.",
            "timeFrame": "1 month after first vaccination i.e.: at Day 31 for all groups except for the MenACWY Group"
          },
          "pred_item": {
            "measure": "Immune response against pooled serogroup B test strains measured by hSBA GMTs",
            "description": "Immune response against pooled serogroup B test strains (fHbp, NadA, PorA, and NHBA) 1 month after the first vaccination, measured by serum bactericidal assay using human complement (hSBA) geometric mean titers (GMTs).",
            "timeFrame": "1 month post-first vaccination (day 31)"
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "hSBA Adjusted GMTs Against Each of the N. Meningitidis Serogroup B Test Strains and N. Meningitidis Serogroups A, C, W-135 and Y, One Month After First Vaccination.",
            "description": "hSBA titers against each of the N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y were calculated in terms of GMTs. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted means were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.",
            "timeFrame": "1 month after first vaccination i.e.: at Day 31 for all groups except for the MenACWY Group."
          },
          "pred_item": {
            "measure": "Immune response against serogroups A, C, W, and Y measured by hSBA GMTs",
            "description": "Immune response against meningococcal serogroups A, C, W, and Y 1 month after the first vaccination, measured by serum bactericidal assay using human complement (hSBA) geometric mean titers (GMTs).",
            "timeFrame": "1 month post-first vaccination (day 31)"
          }
        },
        {
          "ref_idx": 2,
          "pred_idx": 2,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Subjects With hSBA Titers Greater Than or Equal to (≥) the LLOQ Against Each of the N. Meningitidis Serogroup B Test Strains and Against Serogroups A, C, W-135, and Y, One Month After First Vaccination",
            "description": "Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with hSBA titers ≥ LLOQ. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).",
            "timeFrame": "1 month after first vaccination i.e.: at Day 31 for all groups except for the MenACWY Group"
          },
          "pred_item": {
            "measure": "Percentage of participants with hSBA titer ≥LLOQ",
            "description": "Percentage of participants with serum bactericidal assay using human complement (hSBA) titer greater than or equal to the lower limit of quantitation (≥LLOQ) against serogroup B test strains and serogroups A, C, W, and Y.",
            "timeFrame": "At baseline, 1 month post-first vaccination (day 31), and 1 month post-last vaccination (day 91 or day 31 for MenACWY group)"
          }
        },
        {
          "ref_idx": 3,
          "pred_idx": 3,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "measure": "Percentage of Subjects With a 4-fold Increase in hSBA Titers Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135, and Y, One Month After First Vaccination",
            "description": "Immune responses against N. meningitidis serogroup B test strains and N. meningitidis serogroups A, C, W-135, and Y, were calculated in terms of percentage of subjects with a 4-fold increase in hSBA titers. A 4-fold rise is defined as: a) for individuals whose pre-vaccination titers were less than (\\<) the limit of detection (LOD), the post-vaccination titers must have been ≥4-fold the LOD or ≥ the LLOQ, whichever was greater; b) for individuals whose pre-vaccination titers were ≥ the LOD and less than (\\<) the LLOQ, the post-vaccination titers must have been at least 4 times the LLOQ; and c) for individuals whose pre-vaccination titers were ≥ the LLOQ, the post-vaccination titers must have been at least 4 times the pre-vaccination titer. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA).",
            "timeFrame": "1 month after first vaccination versus baseline (i.e.: at Day 31 versus Day 1 for all groups except for the MenACWY Group)"
          },
          "pred_item": {
            "measure": "Percentage of participants with 4-fold increase in hSBA titer",
            "description": "Percentage of participants with a 4-fold increase in serum bactericidal assay using human complement (hSBA) titer from baseline against serogroup B test strains and serogroups A, C, W, and Y.",
            "timeFrame": "1 month post-first vaccination (day 31) and 1 month post-last vaccination (day 91 or day 31 for MenACWY group)"
          }
        },
        {
          "ref_idx": 4,
          "pred_idx": 4,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "measure": "hSBA Adjusted GMRs Against Each of the N. Meningitidis Serogroup B Test Strains and Against N. Meningitidis Serogroups A, C, W-135, and Y, One Month After First Vaccination",
            "description": "hSBA mean ratios at 1 month after the first vaccination versus baseline were calculated in terms of GMRs. i.e. as the anti-logarithm of the mean of the change from baseline of log-transformed titer values at 1 month after first vaccination and Baseline. Serogroup B strains tested were M14459 (factor H binding protein; fHbp), 96217 (Neisserial adhesin A; NadA), NZ98/254 (PorA), and M070241084 (Neisseria heparin binding antigen; NHBA). Adjusted mean were obtained from ANCOVA model fitted to each Serogroup (Strain) individually, study group and center as fixed effects and zero-centered pre-vaccination log-transformed titer as a continuous covariate.",
            "timeFrame": "1 month after first vaccination versus baseline (i.e.: at Day 31 versus Day 1 for all groups except for the MenACWY Group)"
          },
          "pred_item": {
            "measure": "Geometric mean ratio (GMR) of hSBA titers",
            "description": "Geometric mean ratio (GMR) of postvaccination to baseline (prevaccination) serum bactericidal assay using human complement (hSBA) titers against serogroup B test strains and serogroups A, C, W, and Y.",
            "timeFrame": "1 month post-last vaccination (day 91 or day 31 for MenACWY group)"
          }
        },
        {
          "ref_idx": 5,
          "pred_idx": 5,
          "score": 0.97,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Subjects With Any Solicited Local Adverse Events (AEs)",
            "description": "Assessed local AEs were erythema, swelling, induration and pain. Any erythema, swelling and induration is defined as a symptom with a surface diameter equal to or greater than 25 millimeters.",
            "timeFrame": "During the 7 days (including the day of vaccination) after each vaccination i.e after Dose 1 administered at Day 1 (for all groups) and after Dose 2 administered at Day 61 (for all groups except for MenACWY Group)"
          },
          "pred_item": {
            "measure": "Solicited local adverse events",
            "description": "Number and percentage of participants reporting solicited local adverse events (erythema, swelling, induration, and pain at injection site) within 7 days following each vaccine dose.",
            "timeFrame": "Within 7 days following each vaccine dose (day 1 to day 7; day 61 to day 67 for groups receiving two doses)"
          }
        },
        {
          "ref_idx": 6,
          "pred_idx": 6,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Subjects With Any Solicited Systemic AEs",
            "description": "Assessed systemic AEs were arthralgia, fatigue, nausea, headache, myalgia and fever. Any fever is defined as body temperature equal or greater than 38 degrees Celsius.",
            "timeFrame": "During the 7 days (including the day of vaccination) after each vaccination i.e after Dose 1 administered at Day 1 (for all groups) and after Dose 2 administered at Day 61 (for all groups except for MenACWY Group)"
          },
          "pred_item": {
            "measure": "Solicited systemic adverse events",
            "description": "Number and percentage of participants reporting solicited systemic adverse events (arthralgia, fatigue, nausea, headache, myalgia, and fever) within 7 days following each vaccine dose.",
            "timeFrame": "Within 7 days following each vaccine dose (day 1 to day 7; day 61 to day 67 for groups receiving two doses)"
          }
        },
        {
          "ref_idx": 7,
          "pred_idx": 7,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Subjects With Unsolicited AEs",
            "description": "An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e. lack of efficacy), abuse or misuse. An unsolicited AE is an AE that was not solicited using a Subject Diary and that was spontaneously communicated by a subjects/parent(s)/ Legally Acceptable Representative who has signed the informed consent or a solicited local or systemic adverse event that continues beyond the solicited period at day 7 after vaccination.",
            "timeFrame": "During the 30 days (including the day of vaccination) after each vaccination i.e after Dose 1 administered at Day 1 (for all groups) and after Dose 2 administered at Day 61 (for all groups except for MenACWY Group)"
          },
          "pred_item": {
            "measure": "Unsolicited adverse events",
            "description": "Number and percentage of participants reporting unsolicited adverse events during the 30-day postvaccination period following each vaccine dose.",
            "timeFrame": "30 days following each vaccine dose (day 1 to day 31; day 61 to day 91 for groups receiving two doses)"
          }
        },
        {
          "ref_idx": 8,
          "pred_idx": 8,
          "score": 0.82,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Subjects With Serious Adverse Events (SAEs), Medically Attended AEs (MAEs), AEs Leading to Withdrawal, and Adverse Events of Special Interest (AESIs)",
            "description": "SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity or was a congenital anomaly/birth defect in the offspring of a study subject. Medically attended AEs are defined as symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider. AESIs are predefined (serious or non-serious) adverse events of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterize and understand it.",
            "timeFrame": "During the whole study period i.e from Day 1 to Day 91"
          },
          "pred_item": {
            "measure": "Serious adverse events",
            "description": "Number and percentage of participants reporting serious adverse events (SAEs) over the entire study period.",
            "timeFrame": "Throughout the study period (day 1 to day 91 for groups receiving two doses; day 1 to day 31 for MenACWY group)"
          }
        }
      ]
    }
  ]
}